Abstract
Given the remarkable progress that has recently been obtained in animal studies, the clinical use of stem and progenitor cells to correct or replace defective cell populations may soon become a reality. In order to develop effective cell therapies, the location and distribution of these cells must be determined in a non-invasive manner. Magnetic resonance (MR) tracking of magnetically labeled cells following transplantation or transfusion may fulfill this requirement. Indeed, a series of recent studies indicate that MRI cell tracking has great potential for further evaluation and optimization of cell therapy. Due to its biocompatibility and strong effects on T2(*) relaxation, iron oxide nanoparticles appear to be the contrast agent of choice, and several methods now exist to shuttle sufficient amount of these compounds into cells. Most of the tracking work has been carried out in disease models of the central nervous system, but, recently, the infarcted heart has also received attention. With its excellent spatial resolution and the ability to track labeled cells over prolonged periods of time, MR monitoring of cell therapy is likely to become an important technique in the foreseeable future.
Keywords: mr contrast agent, iron oxide, stem cell, progenitor cell, myelin, neurodegeneration, myocardial infarction
Current Pharmaceutical Biotechnology
Title: Monitoring Cell Therapy Using Iron Oxide MR Contrast Agents
Volume: 5 Issue: 6
Author(s): Jeff W. M. Bulte and Dara L. Kraitchman
Affiliation:
Keywords: mr contrast agent, iron oxide, stem cell, progenitor cell, myelin, neurodegeneration, myocardial infarction
Abstract: Given the remarkable progress that has recently been obtained in animal studies, the clinical use of stem and progenitor cells to correct or replace defective cell populations may soon become a reality. In order to develop effective cell therapies, the location and distribution of these cells must be determined in a non-invasive manner. Magnetic resonance (MR) tracking of magnetically labeled cells following transplantation or transfusion may fulfill this requirement. Indeed, a series of recent studies indicate that MRI cell tracking has great potential for further evaluation and optimization of cell therapy. Due to its biocompatibility and strong effects on T2(*) relaxation, iron oxide nanoparticles appear to be the contrast agent of choice, and several methods now exist to shuttle sufficient amount of these compounds into cells. Most of the tracking work has been carried out in disease models of the central nervous system, but, recently, the infarcted heart has also received attention. With its excellent spatial resolution and the ability to track labeled cells over prolonged periods of time, MR monitoring of cell therapy is likely to become an important technique in the foreseeable future.
Export Options
About this article
Cite this article as:
M. Bulte W. Jeff and Kraitchman L. Dara, Monitoring Cell Therapy Using Iron Oxide MR Contrast Agents, Current Pharmaceutical Biotechnology 2004; 5 (6) . https://dx.doi.org/10.2174/1389201043376526
DOI https://dx.doi.org/10.2174/1389201043376526 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Patient-Specific Induced Pluripotent Stem Cell Models in Mitochondrial Diseases
Current Stem Cell Research & Therapy Anti-inflammatory Treatment of Acute Coronary Syndromes
Current Pharmaceutical Design MicroRNA Therapeutics: the Next Magic Bullet?
Mini-Reviews in Medicinal Chemistry How does Chronic Atrial Fibrillation Influence Mortality in the Modern Treatment Era?
Current Cardiology Reviews Characteristics Other than the Diagnostic Criteria Associated with Metabolic Syndrome: An Overview
Current Vascular Pharmacology Recent Advances and Patents on Novel Devices for Minimally Invasive Treatment of Functional Mitral Regurgitation
Recent Patents on Biomedical Engineering (Discontinued) Application and Future Prospect of Extracellular Matrix Targeted Nanomaterials in Tumor Theranostics
Current Drug Targets New Development and Application of Ultrasound Targeted Microbubble Destruction in Gene Therapy and Drug Delivery
Current Gene Therapy Renal and Cardiac Effects of Renal Sympathetic Denervation and Carotid Baroreceptor Stimulation
Current Vascular Pharmacology Basal Septal Hypertrophy
Current Cardiology Reviews GDF 15 - A Novel Biomarker in the Offing for Heart Failure
Current Cardiology Reviews The LIM Protein fhlA is Essential for Heart Chamber Development in Zebrafish Embryos
Current Molecular Medicine p38 Mitogen-Activated Protein Kinase: A Critical Node Linking Insulin Resistance and Cardiovascular Diseases in Type 2 Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Genes and Hypertension
Current Pharmaceutical Design Advanced Glycation End Products: Association with the Pathogenesis of Diseases and the Current Therapeutic Advances
Current Clinical Pharmacology Cardiac Stem Cell-Based Myocardial Regeneration: Towards a Translational Approach
Cardiovascular & Hematological Agents in Medicinal Chemistry Indications for Heart Transplantation in Congenital Heart Disease
Current Cardiology Reviews Aldose Reductase, Still a Compelling Target for Diabetic Neuropathy
Current Drug Targets Endothelin Receptor Antagonists: Another Potential Alternative for Cardiovascular Diseases
Current Drug Targets - Cardiovascular & Hematological Disorders Apelin in the Control of Body Fluid Homeostasis and Cardiovascular Functions
Current Pharmaceutical Design